The Reference Library
for the Peptide Professional

Acknowledge first, then reframe. "You're right that these aren't FDA approved as standalone drugs — and that's an important distinction worth being clear about with patients. What we're talking about is compounding under 503A, which has been part of pharmacy practice for decades. Sermorelin, oxytocin, and several other peptides have been compounded legally for years. The question for you as a prescriber isn't 'is this FDA approved' but 'does the evidence support clinical use, and can I prescribe it within appropriate standard of care?' Many functional medicine and integrative practitioners have developed informed consent processes and monitoring protocols for these compounds. I can share examples if that's useful."

Don't argue with this — it's partially true. Use it as a credibility moment. "That's fair for some compounds. BPC-157, for example, has extensive animal model data from multiple independent labs, but no completed human clinical trials. TB-500 is similar. Where I'd push back slightly is on sermorelin and certain growth hormone secretagogues — there's meaningful human data there. The honest answer is that the evidence varies by compound. For compounds with thinner evidence, practitioners who use them do so based on mechanism plausibility, preclinical data, and clinical observation — and they're transparent with patients about that. Would it help to go through the evidence tier for each compound you're considering?"

This is the opening you want. "You're right that it has been moving fast — and that's exactly why I want to walk you through where things stand today. As of April 15, the FDA announced a July advisory panel to review seven compounds including BPC-157 and TB-500 for restoration to the approved bulks list. In the interim, those compounds were removed from the restricted list. Our pharmacy's compliance team has reviewed this and is compounding under 503A during this interim period with appropriate prescriptions. I'll send you a one-page regulatory status sheet after this meeting — it covers every compound we offer and where it stands today. We update it every time there's a development."

Turn this into a patient safety conversation. "They absolutely can — and many are. The question is what they're getting. Overseas research-grade suppliers have no quality controls, no dosing verification, no pharmaceutical-grade manufacturing standards. Contamination and incorrect concentrations are real documented problems. When a patient comes to you with questions about peptides — and more are coming every month — you have two choices: engage with them and guide them toward a safe, supervised approach, or send them back to figure it out themselves. Prescribers who are proactive about this are building a strong patient loyalty and a new revenue stream. Those who aren't are watching that conversation happen elsewhere."

Respect this concern — it's legitimate. Address it directly. "That's a reasonable concern and I don't want to minimize it. The practitioners who manage liability best in this space do a few things: they use a robust informed consent process that clearly explains the investigational nature of the compound, they document their clinical reasoning, they choose compounds with the strongest preclinical safety profiles, and they monitor patients appropriately. Several of the functional medicine groups doing this at scale have had their approaches reviewed by healthcare attorneys. I can connect you with practitioners who've built out compliant protocols if that would help you feel confident about the framework before you start."